TOPICS / PLAYER

Merck

Merck — partners with Moderna on mRNA-4157/V940 and supplies the pembrolizumab (Keytruda) checkpoint backbone across many vaccine combinations.

Topic2 items2026-06-01

Players

Nouscom4 NEC / NEC OncoImmunity2 Merck2 BioNTech1 Moderna1 Transgene1 Geneos Therapeutics1

Commercial

Individualized neoantigen therapies: exploring one medicine for one patient - Merck.com

Merck explores the concept of 'one medicine for one patient' in individualized neoantigen therapies. As a major payer and partner in the space, Merck’s framing highlights the logistical and economic challenges of personalization that industry must solve for widespread adoption.

news · brief 2026-06-01 · published 2023-04-13

Commercial

What are individualized neoantigen therapies? - Merck.com

Merck provides an overview of individualized neoantigen therapies, likely defining the standard of care or technological requirements for the sector. This educational content from a key industry participant helps standardize market understanding and investment theses.

news · brief 2026-06-01 · published 2026-05-20